Acquisitions10 Jul 2025, 05:17 pm
Senores Pharmaceuticals Acquires 2.97% Additional Stake in Subsidiary Havix Group Inc. D/B/A Aavis Pharmaceuticals
AI Summary
Senores Pharmaceuticals Limited has announced the acquisition of 6730 equity shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals, a subsidiary of the company. This acquisition will increase Senores' shareholding in Havix from 70.07% to 73.04%. The acquisition is being done at an arm's length basis and does not fall under the ambit of related party transactions. The cost of acquisition is USD 181 per equity share. Havix is a US-based company engaged in the business of developing, manufacturing, and supplying various finished formulations with a turnover of USD 19,869,291 for the financial year ended March 31, 2025.
Key Highlights
- Senores Pharmaceuticals to acquire 2.97% additional stake in Havix Group Inc. D/B/A Aavis Pharmaceuticals
- The acquisition will increase Senores' shareholding in Havix from 70.07% to 73.04%
- The acquisition is being done at an arm's length basis
- Havix is a US-based company with a turnover of USD 19,869,291 for the financial year ended March 31, 2025
- The acquisition is subject to the terms and conditions as mentioned in the Share Purchase Agreement (SPA)